Combined interferon alfa and lipsosmal-encapsulated all-trans retinoic acid, including preparation and use
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jan 3, 2002
app pub date -
Mar 16, 2001
filing date -
Mar 31, 2000
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Alfa interferon (.alpha.-IFN or alpha-interferon) and liposomal all-trans retinoic acid is useful in cancer treatment with particular reference to renal cancer. Optionally, a regimen of .alpha.-interferon from about 3 to about 5 million units sc daily and liposomal all-trans retinoic acid at from about 15 mg/m.sup.2 to about 90 mg/m.sup.2, or about 140 mg/m.sup.2, or about 300 mg/m.sup.2 or more. Dosage periodicity of about three times per week for both drugs in about 8 week cycles is useful.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully